Antacids Market To Reach $8.79 Billion By 2030 | CAGR: 3.7%

Antacids Market Growth & Trends

The global antacids market size is expected to reach USD 8.79 billion by 2030, registering a CAGR of 3.7% during the forecast period, according to a new report by Grand View Research, Inc The trend of self-medication for occasional heartburn is one of the major factors driving the market.

Growing geriatric population is expected to positively impact the overall market for antacid. According to the United Nations Department of Economic And Social Affairs (DESA), the global elderly population (60 years and above), was around 962 million in 2017. This number is expected to grow at the fastest rate in Latin America with 71% increase in population aged 60 and over, followed by Asia with 66%, Africa with 64%, North America with 41%, and Europe with 23%.

Key players operating in antacid market focus on product enhancement to cater to patient requirements, such as changing the dosage form into chewable tablets, powder, and jelly. Also, these players are involved in collaborations and acquisitions to expand their market presence. For instance, in 2017, Pfizer, Inc. entered into a strategic agreement with AstraZeneca to acquire one of the antacid brands, Neksium for a value of INR 75 crores in India to boost its product portfolio.

The easy availability of antacids over-the-counter offer growth opportunities for the sales of overall market. Some of the key players areGlaxoSmithKline plc; AstraZeneca; Pfizer, Inc.; Sun Pharmaceuticals Industries Ltd.; Dr. Reddy’s Laboratories Ltd.; Bayer AG; Takeda Pharmaceutical Company Limited.

 Request a free sample copy or view report summary: Antacids Market Report

Antacids Market Report Highlights

•  In 2022, tablet segment led the antacid market due to high efficacy compared to other dosage forms. Liquid is anticipated to be the fastest growing segment due to its palatable taste and preferred choice for children and elderly population

• Retail pharmacy led the distribution channel segment due its accessibility and availability. Online pharmacy is anticipated to be the fastest growing segment due to growing adoption of Pharma 3.0 and consumer awareness

• Asia Pacific is estimated to be the fastest growing region over the forecast period due to presence of key players such as GlaxoSmithKline plc; Pfizer Inc.; and Abbott among others

• North America held the largest market share in 2022 owing to increasing prevalence of different digestive disorders

Antacids Market Segmentation

Grand View Research has segmented the global antacids market based on type, end-use, and region:

Antacids Type Outlook (Revenue, USD Billion, 2018 - 2030)

• Tablet

• Liquid

• Others

Antacids End-use Outlook (Revenue, USD Billion, 2018 - 2030)

• Hospital Pharmacy

• Retail Pharmacy

• Online Pharmacy

Antacids Regional Outlook (Revenue, USD Billion, 2018 - 2030)

• North America

  • U.S.

  • Canada

• Europe

  • UK

  • Germany

  • France

  • Italy

  • Spain

  • Denmark

  • Sweden

  • Norway

• Asia Pacific

  • Japan

  • China

  • India

  • Australia

  • Thailand

  • South Korea

• Latin America

  • Brazil

  • Mexico

  • Argentina

• Middle East and Africa

  • South Africa

  • Saudi Arabia

  • UAE

  • Kuwait

List of Key Players in the Antacids Market

• GlaxoSmithKline plc

• Bayer AG

• Boehringer Ingelheim International GmbH

• Dr. Reddy’s Laboratories Ltd.

• Sanofi

• Reckitt Benckiser Group plc

• Sun Pharmaceuticals Ltd.

• Takeda Pharmaceutical Company Limited

• Pfizer Inc.

• Procter & Gamble